Currentsierra health and lifePolicy 2026T0498CC

Prolotherapy and Platelet Rich Plasma Therapies

Defines UnitedHealthcare Commercial and Individual Exchange medical policy coverage rationale, evidence review, and applicable billing codes for prolotherapy and platelet-rich plasma therapies. Establishes coverage stance and provides referenced procedure codes and descriptions.

Policy Summary

Payersierra health and life

PolicyProlotherapy and Platelet Rich Plasma Therapies

Policy CodePolicy 2026T0498CC

Change TypeTemplate Update / revised

Effective DateJan 1, 2026

Next Review Date

Key ActionClaims for prolotherapy and platelet-rich plasma (PRP) therapies should be considered not medically necessary due to insufficient evidence of efficacy for any condition or indication; include documentation if disputing medical necessity.

SourceLink

POLICY UPDATE CHANGES

01/01/2026 Template Update created shared policy version to support application to Oxford plan membership and updated supporting information, clinical evidence, and references.

2Therapies classified as not medically necessary

5Procedure/HCPCS/CPT codes referenced

lowOverall Evidence Quality

heterogeneousEvidence Consistency

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

This policy (Policy No. 2026T0498CC, effective January 1, 2026) applies to UnitedHealthcare Commercial and Individual Exchange plans and addresses coverage for prolotherapy and platelet-rich plasma (PRP) therapies. The policy scope clarifies that both therapies are classified as not medically necessary (unproven) for any condition due to insufficient evidence of efficacy. Prolotherapy is defined as injections (e.g., hypertonic dextrose, saline, local anesthetic) intended to stimulate tissue repair; PRP is described as an autologous, platelet-concentrated blood product with widely variable preparations. Evidence reviewed includes multiple small RCTs and systematic reviews across indications (e.g., knee and hip osteoarthritis, tendinopathies, low back pain, and wounds), which collectively are limited, heterogeneous, and of low to very low quality, yielding inconsistent outcomes and preventing firm conclusions about net clinical benefit.

Policy metadata — quick view

Policy number2026T0498CC

SubjectProlotherapy and Platelet-Rich Plasma (PRP) Therapies

Effective dateJanuary 1, 2026

StatusCURRENT

Most recent revision01/01/2026: Template Update — created shared policy version to support Oxford plan application; updated supporting information, clinical evidence, and references; archived previous policy version 2025T0498BB

Medical Necessity and Coverage Rationale

Coverage Rationale

Due to insufficient evidence of efficacy, the following are unproven and not medically necessary for any condition or indication:

ALL of the following

Prolotherapy
Platelet-rich plasma

Description: Prolotherapy: Injection of any substance (e.g., dextrose, saline, sarapin, procaine or lidocaine) intended to stimulate the body's healing mechanisms to repair joints and connective tissue. PRP: Autologous blood preparation with a high platelet concentration; PRP preparations are not standardized and vary in composition.

Source descriptions

Evidence summary-based coverage implications

Provider Actions & Operational Guidance

Documentation Required

Coverage Denial Basis

Coverage is denied because current evidence is insufficient to demonstrate clinically meaningful benefit for prolotherapy and PRP across indications. Claims using the listed codes are likely to be reviewed and denied when billed as treatments for musculoskeletal conditions without documentation of a covered exception or mandate.

0232T
G0460
G0465
M0076
P9020
0232T: Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed
G0460: Autologous platelet rich plasma (PRP) or other blood-derived product for nondiabetic chronic wounds/ulcers
G0465: Autologous platelet rich plasma (PRP) or other blood-derived product for diabetic chronic wounds/ulcers, using an FDA-cleared device
M0076: Prolotherapy
P9020: Platelet rich plasma, each unit

Coding

Referenced CPT / HCPCS / Other Codes (provided for reference only)mixed

0232T	Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed
G0460	Autologous platelet rich plasma (PRP) or other blood-derived product for nondiabetic chronic wounds/ulcers (includes, as applicable: administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment).
G0465	Autologous platelet rich plasma (PRP) or other blood-derived product for diabetic chronic wounds/ulcers, using an FDA-cleared device for this indication, (includes as applicable: administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment).
M0076	Prolotherapy.
P9020	Platelet rich plasma, each unit

Background and Evidence Summary

Prolotherapy and PRP are described as biologic/regenerative injection therapies. Prolotherapy typically uses injected agents such as hypertonic dextrose (often with local anesthetic) or other solutions to provoke a localized inflammatory response intended to stimulate tissue repair. PRP is an autologous blood fraction with concentrated platelets and growth factors; PRP preparations vary substantially in platelet and white blood cell content and are not standardized. The source evidence is limited and heterogeneous: many studies are small, use varied preparations and protocols, have short follow-up, and are methodologically inconsistent, so overall study quality is low and outcomes across indications are inconsistent.

Definitions

Evidence snapshot

Revision History

01/01/2026revisedLatest

Template Update created shared policy version to support application to Oxford plan membership and updated supporting information, clinical evidence, and references. Archived previous policy version 2025T0498BB.

Policy Summary

Payersierra health and life

PolicyProlotherapy and Platelet Rich Plasma Therapies

Policy CodePolicy 2026T0498CC

Change TypeTemplate Update / revised

Effective DateJan 1, 2026

Next Review Date

SourceLink

On This Page

Coverage considerations based on condition-specific evidence summaries and guideline statements:

ANY of the following

Low back pain: Mixed/limited evidence from small RCTs and prospective studies; some RCTs report short-term pain/function improvements with PRP versus controls but limitations include small sample sizes, short follow-up, and heterogeneity; further RCTs needed before clinical usefulness is proven.
Wounds: Systematic reviews and HTAs report low-to-moderate strength evidence suggesting PRP may improve healing in hard-to-heal diabetic foot ulcers and possibly venous leg ulcers, but heterogeneous PRP preparation, application, and study quality limit conclusions; more standardized, larger RCTs needed.
Osteoarthritis and tendinopathy: Professional society guidance and systematic reviews generally do not recommend routine use of PRP/prolotherapy for advanced hip/knee OA or certain shoulder conditions; some organizations note PRP may reduce knee OA pain based on low-quality evidence, while others strongly recommend against PRP for knee/hip OA; evidence for tendinopathies is mixed and low quality.
Safety/regulatory: PRP and prolotherapy are procedures not subject to FDA approval; agents used (e.g., dextrose, lidocaine) are FDA-approved for injection but use is off-label for these indications.

Guidance summary: Select professional guidance: AAOS notes PRP may reduce knee OA pain based on low-quality evidence but lacks standardization; NICE recommends PRP for knee OA only with special arrangements or research; ACR strongly recommends against PRP for knee/hip OA; VA/DoD states insufficient evidence to recommend for or against PRP for hip/knee OA.

Denial Risk

Expect limited coverage rationale for many PRP indications

Expect limited coverage rationale for many PRP indications due to heterogeneous preparations, variable platelet/WBC concentrations, and low-quality clinical evidence that fails to show consistent functional benefit.

Prior Authorization

Use with special arrangements or trial enrollment

When PRP or prolotherapy is considered under special arrangements (e.g., employer carve-outs, research programs) or as part of a clinical trial, ensure prior special-approval or trial enrollment documentation is obtained and attached to the authorization/claim.

Documentation Required

Interpret evidence uncertainty when considering PRP

Document uncertainty in the evidence when requesting review: include rationale for therapy selection, prior conservative treatments tried, objective baseline measures, treatment protocol (agent, concentration, volume, number and timing of injections), and measurable follow-up outcomes.

Documentation Required

Documentation & Evidence-Uncertainty Guidance for Reviewers/Providers

Provide clear documentation of medical necessity and of the limited evidence base when submitting claims or prior authorization requests. Reviewers should note the absence of standardized PRP preparation protocols and that available trials are heterogeneous and low quality.

Note

Verify Member Benefits and Mandates

Check member-specific benefit plans and state/Medicare mandate exceptions before authorizing or denying services. Coverage may vary by contract and applicable law.

Note

Use of Third-Party Tools Permitted

Use approved third-party utilization management or clinical decision-support tools where permitted to assist in benefit determination and prior authorization. Documentation from these tools may be submitted to support case review.

Note

Check Medicare/State Mandates

Confirm Medicare, state-mandated coverage, and any plan carve-outs prior to decision. If a mandate requires coverage for a specific PRP indication, follow that requirement and document the legal basis.